Ironwood Pharmaceuticals Inc. (IRWD) intrinsic value & 10-year financials
Ironwood Pharmaceuticals Inc. (IRWD) has a Graham intrinsic value of $1.40 per share. At $3.50 on Oct 17, 2026, the stock trades 150% above that value. Over the last 10 fiscal years revenue grew 0.9% a year to $296.2M, with an average return on invested capital of -64.8%.
- Graham intrinsic value
- $1.40
- Share price (Oct 17, 2026)
- $3.50
- Price vs Graham value
- 150% above
- Market cap
- $570.4M
- Revenue (FY2025)
- $296.2M
- Revenue growth (10-yr CAGR)
- 0.9%
- ROIC (10-yr avg)
- -64.8%
- Free cash flow (FY2025)
- $127.0M
IRWD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $296.2M | $24.0M | $0.15 | $127.0M | 33.3% | -15.2% |
| FY2024 | $351.4M | $880.0K | $0.01 | $103.4M | 26.5% | -45.5% |
| FY2023 | $442.7M | -$1.0B | -$6.45 | $183.2M | -213.5% | -493.7% |
| FY2022 | $410.6M | $175.1M | $0.96 | $273.6M | 61.0% | 40.0% |
| FY2021 | $413.8M | $528.4M | $3.21 | $261.6M | 56.1% | 76.3% |
| FY2020 | $389.5M | $106.2M | $0.66 | $167.0M | 36.7% | -285.9% |
| FY2019 | $428.4M | $21.5M | $0.14 | $3.5M | 28.0% | -51.2% |
| FY2018 | $346.6M | -$282.4M | -$1.85 | -$79.5M | -68.9% | 250.9% |
| FY2017 | $298.3M | -$116.9M | — | -$103.8M | -25.9% | -88.0% |
| FY2016 | $274.0M | -$81.7M | — | -$29.6M | -18.9% | -35.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IRONWOOD PHARMACEUTICALS INC has demonstrated mature, steady growth, with revenue compounding at 0.9% annually over the past decade.
IRONWOOD PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -12.5% ROIC.
IRONWOOD PHARMACEUTICALS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, IRONWOOD PHARMACEUTICALS INC is modeled at 1.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.40 per share.